Compare RUN & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | WGS |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Industrial Machinery/Components | Retail: Computer Software & Peripheral Equipment |
| Sector | Miscellaneous | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.0B |
| IPO Year | 2015 | N/A |
| Metric | RUN | WGS |
|---|---|---|
| Price | $12.50 | $66.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 7 |
| Target Price | $19.10 | ★ $130.71 |
| AVG Volume (30 Days) | ★ 6.9M | 645.5K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.35 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $858,578,000.00 | N/A |
| Revenue This Year | $1.08 | $29.98 |
| Revenue Next Year | $4.42 | $25.92 |
| P/E Ratio | ★ $7.46 | $1,251.58 |
| Revenue Growth | ★ 12.97 | N/A |
| 52 Week Low | $5.38 | $55.17 |
| 52 Week High | $22.44 | $170.87 |
| Indicator | RUN | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 42.38 | 46.08 |
| Support Level | $12.01 | $61.55 |
| Resistance Level | $13.57 | $95.75 |
| Average True Range (ATR) | 0.73 | 4.33 |
| MACD | 0.14 | 0.78 |
| Stochastic Oscillator | 17.54 | 69.56 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.